0
0
10/31/22 at 6:20am
Organization
Cancertherapyadvisor.com
Author
Natasha Persaud
25 words
0
Comments
Adding cediranib to olaparib more than doubled the median radiographic progression-free survival.
You are the first to view
https://www.cancertherapyadvisor.com/home/cancer-topics/prostate-cancer/olaparib-plus-cediranib-for-mcrpc-lowers-radiographic-progression-risk-2/
Create an account
or login to join the discussion